Are We Studying Non-Coding RNAs Correctly? Lessons from nc886
Abstract
:1. Introduction
2. Lessons from nc886
2.1. nc886 Had Been Misidentified
2.2. What Is Measured versus What Really Exists; Are They the Same?
2.3. The Mistaken Identity Misleads Functional Approaches
2.4. Features of ncRNA also Matter When Designing Gain-of-Function Experiments
2.5. Choosing a KD Method
2.6. Are We Evaluating KD Efficiency Correctly? Importance of Assays
3. Suggestions from the nc886 Lesson, When Studying an ncRNA
3.1. Are We Looking at ncRNA Molecules Correctly?
3.2. Are We Properly Performing Gain- and Loss-of-Function Approaches Based on Correct Identity and Features?
4. Summary of Cautions for Studying an ncRNA
4.1. A Prerequisite for Studying an ncRNA Is to Know Its Features, Including
- -
- What is its exact sequence? The precise 5′- to 3′-end should be determined in order to correctly design overexpression and KD experiments.
- -
- Which RNA polymerase (I, II, or III) transcribes it?
- -
- Where is it located (nuclear or cytoplasmic, in a protein complex or chromatin-associated, in a specific subcellular organelle, etc.)?
- -
- Is it a de novo transcript or a processing product from a pre-existing RNA?
- -
- How abundant is it in a cell?
4.2. Gain-of-Function Experiments
- -
- In a plasmid-based overexpression system, the precise sequence should be placed under a correct promoter of reasonable strength.
- -
- For small ncRNAs, a synthetic modified oligoribonucleotide can be considered.
- -
- For small ncRNAs without concrete evidence that they are bona fide miRNAs, an siRNA-like duplex must not be used.
4.3. Loss-of-Function Experiments
- -
- For KD, modified ASO should be considered with a higher priority than an siRNA.
- -
- KO by CRISPR-Cas would be the best, if KO cells can be created.
4.4. Assays for Overexpression or KD and Assessment of Cellular Phenotypes
- -
- Overexpression or KD should be validated by a proper measurement; Northern hybridization is better than qRT-PCR.
- -
- In addition to measurement, validation by a functional assay is desirable.
- -
- A functional assay is absolutely required when a synthetic RNA is used for overexpression.
- -
- A functional assay can include the use of cellular phenotypes, gene expression profiles, or the measurement of a particular protein activity or pathway. The more specific, the better.
- -
- The phenotypic data from overexpression and from a KD or KO experiment should complement each other.
5. Concluding Remark
Funding
Acknowledgments
Conflicts of Interest
References
- Djebali, S.; Davis, C.A.; Merkel, A.; Dobin, A.; Lassmann, T.; Mortazavi, A.; Tanzer, A.; Lagarde, J.; Lin, W.; Schlesinger, F.; et al. Landscape of transcription in human cells. Nature 2012, 489, 101–108. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Storz, G.; Altuvia, S.; Wassarman, K.M. An abundance of RNA regulators. Annu. Rev. Biochem. 2005, 74, 199–217. [Google Scholar] [CrossRef] [PubMed]
- Lee, R.C.; Feinbaum, R.L.; Ambros, V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75, 843–854. [Google Scholar] [CrossRef]
- Wightman, B.; Ha, I.; Ruvkun, G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993, 75, 855–862. [Google Scholar] [CrossRef]
- Lagos-Quintana, M.; Rauhut, R.; Lendeckel, W.; Tuschl, T. Identification of novel genes coding for small expressed RNAs. Science 2001, 294, 853–858. [Google Scholar] [CrossRef] [Green Version]
- Lau, N.C.; Lim, L.P.; Weinstein, E.G.; Bartel, D.P. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 2001, 294, 858–862. [Google Scholar] [CrossRef] [Green Version]
- Lee, R.C.; Ambros, V. An extensive class of small RNAs in Caenorhabditis elegans. Science 2001, 294, 862–864. [Google Scholar] [CrossRef] [Green Version]
- Margulies, M.; Egholm, M.; Altman, W.E.; Attiya, S.; Bader, J.S.; Bemben, L.A.; Berka, J.; Braverman, M.S.; Chen, Y.J.; Chen, Z.; et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature 2005, 437, 376–380. [Google Scholar] [CrossRef]
- Reuter, J.A.; Spacek, D.V.; Snyder, M.P. High-throughput sequencing technologies. Mol. Cell 2015, 58, 586–597. [Google Scholar] [CrossRef] [Green Version]
- Lee, K.; Kunkeaw, N.; Jeon, S.H.; Lee, I.; Johnson, B.H.; Kang, G.Y.; Bang, J.Y.; Park, H.S.; Leelayuwat, C.; Lee, Y.S. Precursor miR-886, a novel noncoding RNA repressed in cancer, associates with PKR and modulates its activity. RNA 2011, 17, 1076–1089. [Google Scholar] [CrossRef] [Green Version]
- Ambros, V.; Bartel, B.; Bartel, D.P.; Burge, C.B.; Carrington, J.C.; Chen, X.; Dreyfuss, G.; Eddy, S.R.; Griffiths-Jones, S.; Marshall, M.; et al. A uniform system for microRNA annotation. RNA 2003, 9, 277–279. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ha, M.; Kim, V.N. Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 2014, 15, 509–524. [Google Scholar] [CrossRef] [PubMed]
- Bartel, D.P. MicroRNAs: Target recognition and regulatory functions. Cell 2009, 136, 215–233. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Landgraf, P.; Rusu, M.; Sheridan, R.; Sewer, A.; Iovino, N.; Aravin, A.; Pfeffer, S.; Rice, A.; Kamphorst, A.O.; Landthaler, M.; et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007, 129, 1401–1414. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yang, J.H.; Shao, P.; Zhou, H.; Chen, Y.Q.; Qu, L.H. deepBase: A database for deeply annotating and mining deep sequencing data. Nucleic Acids Res. 2010, 38, D123–D130. [Google Scholar] [CrossRef] [PubMed]
- Minones-Moyano, E.; Friedlander, M.R.; Pallares, J.; Kagerbauer, B.; Porta, S.; Escaramis, G.; Ferrer, I.; Estivill, X.; Marti, E. Upregulation of a small vault RNA (svtRNA2-1a) is an early event in Parkinson disease and induces neuronal dysfunction. RNA Biol. 2013, 10, 1093–1106. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fort, R.S.; Garat, B.; Sotelo-Silveira, J.R.; Duhagon, M.A. vtRNA2-1/nc886 Produces a Small RNA That Contributes to Its Tumor Suppression Action through the microRNA Pathway in Prostate Cancer. Noncoding RNA 2020, 6, 7. [Google Scholar] [CrossRef] [Green Version]
- Rigoutsos, I.; Londin, E.; Kirino, Y. Short RNA regulators: The past, the present, the future, and implications for precision medicine and health disparities. Curr. Opin. Biotechnol. 2019, 58, 202–210. [Google Scholar] [CrossRef]
- Lee, K.S.; Park, J.L.; Lee, K.; Richardson, L.E.; Johnson, B.H.; Lee, H.S.; Lee, J.S.; Kim, S.B.; Kwon, O.H.; Song, K.S.; et al. nc886, a non-coding RNA of anti-proliferative role, is suppressed by CpG DNA methylation in human gastric cancer. Oncotarget 2014, 5, 3944–3955. [Google Scholar] [CrossRef] [Green Version]
- Lee, H.S.; Lee, K.; Jang, H.J.; Lee, G.K.; Park, J.L.; Kim, S.Y.; Kim, S.B.; Johnson, B.H.; Zo, J.I.; Lee, J.S.; et al. Epigenetic silencing of the non-coding RNA nc886 provokes oncogenes during human esophageal tumorigenesis. Oncotarget 2014, 5, 3472–3481. [Google Scholar] [CrossRef] [Green Version]
- Jang, H.J.; Lee, H.S.; Burt, B.M.; Lee, G.K.; Yoon, K.A.; Park, Y.Y.; Sohn, B.H.; Kim, S.B.; Kim, M.S.; Lee, J.M.; et al. Integrated genomic analysis of recurrence-associated small non-coding RNAs in oesophageal cancer. Gut 2016, 66, 215–225. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ahn, J.H.; Lee, H.S.; Lee, J.S.; Lee, Y.S.; Park, J.L.; Kim, S.Y.; Hwang, J.A.; Kunkeaw, N.; Jung, S.Y.; Kim, T.J.; et al. nc886 is induced by TGF-beta and suppresses the microRNA pathway in ovarian cancer. Nat. Commun. 2018, 9, 1166. [Google Scholar] [CrossRef] [PubMed]
- Nandy, C.; Mrazek, J.; Stoiber, H.; Grasser, F.A.; Huttenhofer, A.; Polacek, N. Epstein-barr virus-induced expression of a novel human vault RNA. J. Mol. Biol. 2009, 388, 776–784. [Google Scholar] [CrossRef] [PubMed]
- Kong, L.; Hao, Q.; Wang, Y.; Zhou, P.; Zou, B.; Zhang, Y.X. Regulation of p53 expression and apoptosis by vault RNA2-1-5p in cervical cancer cells. Oncotarget 2015, 6, 28371–28388. [Google Scholar] [CrossRef] [PubMed]
- Pillai, M.M.; Yang, X.; Balakrishnan, I.; Bemis, L.; Torok-Storb, B. MiR-886-3p down regulates CXCL12 (SDF1) expression in human marrow stromal cells. PLoS ONE 2010, 5, e14304. [Google Scholar] [CrossRef] [Green Version]
- Treppendahl, M.B.; Qiu, X.; Sogaard, A.; Yang, X.; Nandrup-Bus, C.; Hother, C.; Andersen, M.K.; Kjeldsen, L.; Mollgard, L.; Hellstrom-Lindberg, E.; et al. Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AML. Blood 2012, 119, 206–216. [Google Scholar] [CrossRef]
- Park, J.L.; Lee, Y.S.; Song, M.J.; Hong, S.H.; Ahn, J.H.; Seo, E.H.; Shin, S.P.; Lee, S.J.; Johnson, B.H.; Stampfer, M.R.; et al. Epigenetic regulation of RNA polymerase III transcription in early breast tumorigenesis. Oncogene 2017, 36, 6793–6804. [Google Scholar] [CrossRef] [Green Version]
- Chen, C.; Ridzon, D.A.; Broomer, A.J.; Zhou, Z.; Lee, D.H.; Nguyen, J.T.; Barbisin, M.; Xu, N.L.; Mahuvakar, V.R.; Andersen, M.R.; et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005, 33, e179. [Google Scholar] [CrossRef]
- Perfetti, A.; Greco, S.; Bugiardini, E.; Cardani, R.; Gaia, P.; Gaetano, C.; Meola, G.; Martelli, F. Plasma microRNAs as biomarkers for myotonic dystrophy type 1. Neuromuscul. Disord. 2014, 24, 509–515. [Google Scholar] [CrossRef] [Green Version]
- Schou, J.V.; Rossi, S.; Jensen, B.V.; Nielsen, D.L.; Pfeiffer, P.; Hogdall, E.; Yilmaz, M.; Tejpar, S.; Delorenzi, M.; Kruhoffer, M.; et al. miR-345 in metastatic colorectal cancer: A non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan. PLoS ONE 2014, 9, e99886. [Google Scholar] [CrossRef]
- Suojalehto, H.; Lindstrom, I.; Majuri, M.L.; Mitts, C.; Karjalainen, J.; Wolff, H.; Alenius, H. Altered microRNA expression of nasal mucosa in long-term asthma and allergic rhinitis. Int. Arch. Allergy Immunol. 2014, 163, 168–178. [Google Scholar] [CrossRef] [PubMed]
- Dettmer, M.S.; Perren, A.; Moch, H.; Komminoth, P.; Nikiforov, Y.E.; Nikiforova, M.N. MicroRNA profile of poorly differentiated thyroid carcinomas: New diagnostic and prognostic insights. J. Mol. Endocrinol. 2014, 52, 181–189. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Krintel, S.B.; Dehlendorff, C.; Hetland, M.L.; Horslev-Petersen, K.; Andersen, K.K.; Junker, P.; Podenphant, J.; Ellingsen, T.; Ahlquist, P.; Lindegaard, H.M.; et al. Prediction of treatment response to adalimumab: A double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis. Pharm. J. 2016, 16, 141–146. [Google Scholar] [CrossRef] [PubMed]
- Gao, W.; Shen, H.; Liu, L.; Xu, J.; Shu, Y. MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. J. Cancer Res. Clin. Oncol. 2011, 137, 557–566. [Google Scholar] [CrossRef] [PubMed]
- Yu, X.F.; Zou, J.; Bao, Z.J.; Dong, J. miR-93 suppresses proliferation and colony formation of human colon cancer stem cells. World J. Gastroenterol. 2011, 17, 4711–4717. [Google Scholar] [CrossRef]
- Xiao, W.; Bao, Z.X.; Zhang, C.Y.; Zhang, X.Y.; Shi, L.J.; Zhou, Z.T.; Jiang, W.W. Upregulation of miR-31* is negatively associated with recurrent/newly formed oral leukoplakia. PLoS ONE 2012, 7, e38648. [Google Scholar] [CrossRef]
- Cui, F.M.; Li, J.X.; Chen, Q.; Du, H.B.; Zhang, S.Y.; Nie, J.H.; Cao, J.P.; Zhou, P.K.; Hei, T.K.; Tong, J. Radon-induced alterations in micro-RNA expression profiles in transformed BEAS2B cells. J. Toxicol. Environ. Health A 2013, 76, 107–119. [Google Scholar] [CrossRef]
- Lam, J.K.; Chow, M.Y.; Zhang, Y.; Leung, S.W. siRNA Versus miRNA as Therapeutics for Gene Silencing. Mol. Ther. Nucleic Acids 2015, 4, e252. [Google Scholar] [CrossRef] [Green Version]
- Saxena, S.; Jonsson, Z.O.; Dutta, A. Small RNAs with imperfect match to endogenous mRNA repress translation. Implications for off-target activity of small inhibitory RNA in mammalian cells. J. Biol. Chem. 2003, 278, 44312–44319. [Google Scholar] [CrossRef] [Green Version]
- Hutvagner, G.; Zamore, P.D. A microRNA in a multiple-turnover RNAi enzyme complex. Science 2002, 297, 2056–2060. [Google Scholar] [CrossRef] [Green Version]
- Zhang, L.L.; Wu, J.; Liu, Q.; Zhang, Y.; Sun, Z.L.; Jing, H. MiR-886-5p inhibition inhibits growth and induces apoptosis of MCF7 cells. Asian Pac. J. Cancer Prev. 2014, 15, 1511–1515. [Google Scholar] [CrossRef] [PubMed]
- Tahiri, A.; Leivonen, S.K.; Luders, T.; Steinfeld, I.; Ragle Aure, M.; Geisler, J.; Makela, R.; Nord, S.; Riis, M.L.; Yakhini, Z.; et al. Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors. Carcinogenesis 2014, 35, 76–85. [Google Scholar] [CrossRef] [PubMed]
- Xiong, Y.; Zhang, L.; Holloway, A.K.; Wu, X.; Su, L.; Kebebew, E. MiR-886-3p regulates cell proliferation and migration, and is dysregulated in familial non-medullary thyroid cancer. PLoS ONE 2011, 6, e24717. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nordentoft, I.; Birkenkamp-Demtroder, K.; Agerbaek, M.; Theodorescu, D.; Ostenfeld, M.S.; Hartmann, A.; Borre, M.; Orntoft, T.F.; Dyrskjot, L. miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Med. Genom. 2012, 5, 40. [Google Scholar] [CrossRef] [Green Version]
- Cao, J.; Song, Y.; Bi, N.; Shen, J.; Liu, W.; Fan, J.; Sun, G.; Tong, T.; He, J.; Shi, Y.; et al. DNA methylation-mediated repression of miR-886-3p predicts poor outcome of human small cell lung cancer. Cancer Res. 2013, 73, 3326–3335. [Google Scholar] [CrossRef] [Green Version]
- Li, J.H.; Xiao, X.; Zhang, Y.N.; Wang, Y.M.; Feng, L.M.; Wu, Y.M.; Zhang, Y.X. MicroRNA miR-886-5p inhibits apoptosis by down-regulating Bax expression in human cervical carcinoma cells. Gynecol. Oncol. 2011, 120, 145–151. [Google Scholar] [CrossRef]
- Hu, Z.; Zhang, H.; Tang, L.; Lou, M.; Geng, Y. Silencing nc886, a Non-Coding RNA, Induces Apoptosis of Human Endometrial Cancer Cells-1A In Vitro. Med. Sci. Monit. 2017, 23, 1317–1324. [Google Scholar] [CrossRef] [Green Version]
- Oler, A.J.; Alla, R.K.; Roberts, D.N.; Wong, A.; Hollenhorst, P.C.; Chandler, K.J.; Cassiday, P.A.; Nelson, C.A.; Hagedorn, C.H.; Graves, B.J.; et al. Human RNA polymerase III transcriptomes and relationships to Pol II promoter chromatin and enhancer-binding factors. Nat. Struct. Mol. Biol. 2010, 17, 620–628. [Google Scholar] [CrossRef]
- Canella, D.; Praz, V.; Reina, J.H.; Cousin, P.; Hernandez, N. Defining the RNA polymerase III transcriptome: Genome-wide localization of the RNA polymerase III transcription machinery in human cells. Genome Res. 2010, 20, 710–721. [Google Scholar] [CrossRef] [Green Version]
- Moqtaderi, Z.; Wang, J.; Raha, D.; White, R.J.; Snyder, M.; Weng, Z.; Struhl, K. Genomic binding profiles of functionally distinct RNA polymerase III transcription complexes in human cells. Nat. Struct. Mol. Biol. 2010, 17, 635–640. [Google Scholar] [CrossRef]
- Schramm, L.; Hernandez, N. Recruitment of RNA polymerase III to its target promoters. Genes Dev. 2002, 16, 2593–2620. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kessler, A.C.; Maraia, R.J. The nuclear and cytoplasmic activities of RNA polymerase III, and an evolving transcriptome for surveillance. Nucleic Acids Res. 2021, 49, 12017–12034. [Google Scholar] [CrossRef] [PubMed]
- Im, W.R.; Lee, H.S.; Lee, Y.S.; Lee, J.S.; Jang, H.J.; Kim, S.Y.; Park, J.L.; Lee, Y.; Kim, M.S.; Lee, J.M.; et al. A Regulatory Noncoding RNA, nc886, Suppresses Esophageal Cancer by Inhibiting the AKT Pathway and Cell Cycle Progression. Cells 2020, 9, 801. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, F.; Chen, Y.; Zhang, Z.; Ouyang, J.; Wang, Y.; Yan, R.; Huang, S.; Gao, G.F.; Guo, G.; Chen, J.L. Robust expression of vault RNAs induced by influenza A virus plays a critical role in suppression of PKR-mediated innate immunity. Nucleic Acids Res. 2015, 43, 10321–10337. [Google Scholar] [CrossRef] [PubMed]
- Fort, R.S.; Matho, C.; Geraldo, M.V.; Ottati, M.C.; Yamashita, A.S.; Saito, K.C.; Leite, K.R.M.; Mendez, M.; Maedo, N.; Mendez, L.; et al. Nc886 is epigenetically repressed in prostate cancer and acts as a tumor suppressor through the inhibition of cell growth. BMC Cancer 2018, 18, 127. [Google Scholar] [CrossRef] [Green Version]
- Crooke, S.T.; Liang, X.H.; Baker, B.F.; Crooke, R.M. Antisense technology: A review. J. Biol. Chem. 2021, 296, 100416. [Google Scholar] [CrossRef] [PubMed]
- Lennox, K.A.; Behlke, M.A. Cellular localization of long non-coding RNAs affects silencing by RNAi more than by antisense oligonucleotides. Nucleic Acids Res. 2016, 44, 863–877. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jeon, S.H.; Lee, K.; Lee, K.S.; Kunkeaw, N.; Johnson, B.H.; Holthauzen, L.M.; Gong, B.; Leelayuwat, C.; Lee, Y.S. Characterization of the direct physical interaction of nc886, a cellular non-coding RNA, and PKR. FEBS Lett. 2012, 586, 3477–3484. [Google Scholar] [CrossRef] [Green Version]
- Calderon, B.M.; Conn, G.L. Human noncoding RNA 886 (nc886) adopts two structurally distinct conformers that are functionally opposing regulators of PKR. RNA 2017, 23, 557–566. [Google Scholar] [CrossRef]
- Lee, Y.S.; Kunkeaw, N.; Lee, Y.S. Protein kinase R and its cellular regulators in cancer: An active player or a surveillant? Wiley Interdiscip. Rev. RNA 2020, 11, e1558. [Google Scholar] [CrossRef] [PubMed]
- Cole, J.L. Activation of PKR: An open and shut case? Trends Biochem. Sci. 2007, 32, 57–62. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yoo, B.H.; Bochkareva, E.; Bochkarev, A.; Mou, T.C.; Gray, D.M. 2′-O-methyl-modified phosphorothioate antisense oligonucleotides have reduced non-specific effects in vitro. Nucleic Acids Res. 2004, 32, 2008–2016. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ideue, T.; Hino, K.; Kitao, S.; Yokoi, T.; Hirose, T. Efficient oligonucleotide-mediated degradation of nuclear noncoding RNAs in mammalian cultured cells. RNA 2009, 15, 1578–1587. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kunkeaw, N.; Jeon, S.H.; Lee, K.; Johnson, B.H.; Tanasanvimon, S.; Javle, M.; Pairojkul, C.; Chamgramol, Y.; Wongfieng, W.; Gong, B.; et al. Cell death/proliferation roles for nc886, a non-coding RNA, in the protein kinase R pathway in cholangiocarcinoma. Oncogene 2013, 32, 3722–3731. [Google Scholar] [CrossRef] [Green Version]
- Lee, E.K.; Hong, S.H.; Shin, S.; Lee, H.S.; Lee, J.S.; Park, E.J.; Choi, S.S.; Min, J.W.; Park, D.; Hwang, J.A.; et al. nc886, a non-coding RNA and suppressor of PKR, exerts an oncogenic function in thyroid cancer. Oncotarget 2016, 7, 75000–75012. [Google Scholar] [CrossRef] [Green Version]
- Kunkeaw, N.; Lee, Y.S.; Im, W.R.; Jang, J.J.; Song, M.J.; Yang, B.; Park, J.L.; Kim, S.Y.; Ku, Y.; Kim, Y.; et al. Mechanism mediated by a noncoding RNA, nc886, in the cytotoxicity of a DNA-reactive compound. Proc. Natl. Acad. Sci. USA 2019, 116, 8289–8294. [Google Scholar] [CrossRef] [Green Version]
- Lee, Y.S.; Bao, X.; Lee, H.H.; Jang, J.J.; Saruuldalai, E.; Park, G.; Im, W.R.; Park, J.L.; Kim, S.Y.; Shin, S.; et al. Nc886, a Novel Suppressor of the Type I Interferon Response Upon Pathogen Intrusion. Int. J. Mol. Sci. 2021, 22, 2003. [Google Scholar] [CrossRef]
- Mahishi, L.H.; Hart, R.P.; Lynch, D.R.; Ratan, R.R. miR-886-3p levels are elevated in Friedreich ataxia. J. Neurosci. 2012, 32, 9369–9373. [Google Scholar] [CrossRef]
- Cazenave, C.; Frank, P.; Toulme, J.J.; Busen, W. Characterization and subcellular localization of ribonuclease H activities from Xenopus laevis oocytes. J. Biol. Chem. 1994, 269, 25185–25192. [Google Scholar] [CrossRef]
- Li, L.; Chang, H.Y. Physiological roles of long noncoding RNAs: Insight from knockout mice. Trends Cell Biol. 2014, 24, 594–602. [Google Scholar] [CrossRef] [Green Version]
- Hoerter, J.A.; Krishnan, V.; Lionberger, T.A.; Walter, N.G. siRNA-like double-stranded RNAs are specifically protected against degradation in human cell extract. PLoS ONE 2011, 6, e20359. [Google Scholar] [CrossRef] [PubMed]
- Grimm, D.; Streetz, K.L.; Jopling, C.L.; Storm, T.A.; Pandey, K.; Davis, C.R.; Marion, P.; Salazar, F.; Kay, M.A. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006, 441, 537–541. [Google Scholar] [CrossRef] [PubMed]
- Jiang, F.; Doudna, J.A. CRISPR-Cas9 Structures and Mechanisms. Annu. Rev. Biophys. 2017, 46, 505–529. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lee, Y.S. Are We Studying Non-Coding RNAs Correctly? Lessons from nc886. Int. J. Mol. Sci. 2022, 23, 4251. https://doi.org/10.3390/ijms23084251
Lee YS. Are We Studying Non-Coding RNAs Correctly? Lessons from nc886. International Journal of Molecular Sciences. 2022; 23(8):4251. https://doi.org/10.3390/ijms23084251
Chicago/Turabian StyleLee, Yong Sun. 2022. "Are We Studying Non-Coding RNAs Correctly? Lessons from nc886" International Journal of Molecular Sciences 23, no. 8: 4251. https://doi.org/10.3390/ijms23084251
APA StyleLee, Y. S. (2022). Are We Studying Non-Coding RNAs Correctly? Lessons from nc886. International Journal of Molecular Sciences, 23(8), 4251. https://doi.org/10.3390/ijms23084251